Key result
GILZ deficiency amplifies angiotensin II-induced LV hypertrophy by ~80%, worsening diastolic dysfunction.
Why the study?
There are no effective strategies to counteract hypertrophy in heart failure, and the role of glucocorticoid-induced leucine zipper (GILZ) in cardiac biology is unknown.
Does the deficit of glucocorticoid-induced leucine zipper (GILZ) amplify angiotensin II-induced cardiomyocyte hypertrophy and diastolic dysfunction in mice?
Does the deficit of glucocorticoid-induced leucine zipper (GILZ) amplify angiotensin II-induced cardiomyocyte hypertrophy and diastolic dysfunction in mice?
GILZ appears to be a novel mechanistic element in cardiovascular pathology, as its absence exacerbates Ang II-induced cardiac hypertrophy and diastolic dysfunction.
Answers are grounded in this paper and cite their sources.
GILZ modulation should not yet inform clinical care for diastolic dysfunction; leaves open its role as a therapeutic target in human hypertensive remodeling.
Poor prognosis in heart failure and the lack of real breakthrough strategies validate targeting myocardial remodelling and the intracellular signalling involved in this process. So far, there are no effective strategies to counteract hypertrophy, an independent predictor of heart failure progression and death. Glucocorticoid-induced leucine zipper (GILZ) is involved in inflammatory signalling, but its role in cardiac biology is unknown. Using GILZ-knockout (KO) mice and an experimental model of hypertrophy and diastolic dysfunction, we addressed the role of GILZ in adverse myocardial remodelling. Infusion of angiotensin II (Ang II) resulted in myocardial dysfunction, inflammation, apoptosis, fibrosis, capillary rarefaction and hypertrophy. Interestingly, GILZ-KO showed more evident diastolic dysfunction and aggravated hypertrophic response compared with WT after Ang II administration. Both cardiomyocyte and left ventricular hypertrophy were more pronounced in GILZ-KO mice. On the other hand, Ang II-induced inflammatory and fibrotic phenomena, cell death and reduction in microvascular density, remained invariant between the WT and KO groups. The analysis of regulators of hypertrophic response, GATA4 and FoxP3, demonstrated an up-regulation in WT mice infused with Ang II; conversely, such an increase did not occur in GILZ-KO hearts. These data on myocardial response to Ang II in mice lacking GILZ indicate that this protein is a new element that can be mechanistically involved in cardiovascular pathology.
No takes yet. Share an insight, caveat, or question.
Cappetta et al. (2020) studied Angiotensin II-induced cardiac hypertrophy and diastolic dysfunction. GILZ genetic ablation with Angiotensin II infusion vs. Wild-type mice with Angiotensin II infusion was evaluated on Left ventricular wall thickness-to-bodyweight ratio increase (p=<0.05). GILZ deficiency amplified angiotensin II-induced left ventricular wall thickness-to-bodyweight ratio by 80% compared to 25% in wild-type mice (P<0.05), worsening diastolic dysfunction.
Synapse has enriched 10 related papers. Consider them for comparative context: